Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Sanofi-Aventis |
---|---|
Information provided by: | Sanofi-Aventis |
ClinicalTrials.gov Identifier: | NCT00232310 |
Double blind study to assess versus placebo the efficacy of SSR149744C for the conversion of atrial fibrillation/flutter to sinus rhythm at the time of the planned electrical cardioversion.
Condition | Intervention | Phase |
---|---|---|
Atrial Fibrillation Atrial Flutter |
Drug: SSR149744C |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744C 300 or 600 mg for the Conversion of Atrial Fibrillation / Flutter |
Enrollment: | 150 |
Study Start Date: | October 2005 |
Study Completion Date: | April 2006 |
Primary Completion Date: | April 2006 (Final data collection date for primary outcome measure) |
This is a dose ranging multicenter, multinational, randomized, double blind, placebo controlled, parallel arm study. Patients with AF/AFL will be randomized to one of two doses of SSR149744C. The efficacy of SSR149744C will be based on the proportion of patients converting to normal sinus rhythm at the end of the treatment period (48 hours post first dose). Patients will receive the study drug on D1 and D2. Patients not converting pharmacologically to sinus rhythm will undergo an electrical cardioversion on D3.
Ages Eligible for Study: | 21 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
MAIN CRITERIA (non-exhaustive list):
United States, New Jersey | |
Sanofi-Aventis Administrative Office | |
Bridgewater, New Jersey, United States, 08807 | |
Canada | |
Sanofi-Aventis Administrative Office | |
Laval, Canada | |
Czech Republic | |
Sanofi-Aventis Administrative Office | |
Praha, Czech Republic | |
France | |
Sanofi-Aventis Administrative Office | |
Paris, France | |
Germany | |
Sanofi-Aventis Administrative Office | |
Berlin, Germany | |
Hungary | |
Sanofi-Aventis Administrative Office | |
Budapest, Hungary | |
Italy | |
Sanofi-Aventis Administrative Office | |
Milano, Italy | |
Netherlands | |
Sanofi-Aventis Administrative Office | |
Gouda, Netherlands | |
Portugal | |
Sanofi-Aventis Administrative Office | |
Porto Salvo, Portugal |
Study Director: | ICD CSD | Sanofi-Aventis |
Responsible Party: | sanofi-aventis ( ICD Study Director ) |
Study ID Numbers: | DRI5760 |
Study First Received: | October 3, 2005 |
Last Updated: | December 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00232310 History of Changes |
Health Authority: | United States: Food and Drug Administration; Italy: The Italian Medicines Agency; Germany: Federal Institute for Drugs and Medical Devices |
Atrial Fibrillation Atrial Flutter Electric Countershock |
Heart Diseases Atrial Fibrillation Atrial Flutter Arrhythmias, Cardiac |
Pathologic Processes Heart Diseases Cardiovascular Diseases |
Atrial Fibrillation Atrial Flutter Arrhythmias, Cardiac |